Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Bought by Allianz Asset Management GmbH

Allianz Asset Management GmbH raised its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBHFree Report) by 26.3% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 119,244 shares of the medical equipment provider’s stock after purchasing an additional 24,828 shares during the period. Allianz Asset Management GmbH owned about 0.06% of Zimmer Biomet worth $14,512,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Norges Bank acquired a new stake in shares of Zimmer Biomet during the fourth quarter valued at $266,896,000. American Century Companies Inc. boosted its stake in shares of Zimmer Biomet by 21.2% during the third quarter. American Century Companies Inc. now owns 4,863,741 shares of the medical equipment provider’s stock valued at $545,809,000 after acquiring an additional 852,186 shares during the last quarter. Van ECK Associates Corp boosted its stake in shares of Zimmer Biomet by 23.7% during the fourth quarter. Van ECK Associates Corp now owns 2,838,558 shares of the medical equipment provider’s stock valued at $345,452,000 after acquiring an additional 543,344 shares during the last quarter. Qube Research & Technologies Ltd acquired a new stake in shares of Zimmer Biomet during the third quarter valued at $57,972,000. Finally, Primecap Management Co. CA boosted its stake in shares of Zimmer Biomet by 10.5% during the fourth quarter. Primecap Management Co. CA now owns 5,086,578 shares of the medical equipment provider’s stock valued at $619,037,000 after acquiring an additional 484,151 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Stock Performance

Shares of NYSE:ZBH opened at $115.15 on Monday. The company has a market cap of $23.69 billion, a P/E ratio of 24.92, a PEG ratio of 2.07 and a beta of 1.02. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.80 and a current ratio of 1.66. Zimmer Biomet Holdings, Inc. has a one year low of $102.00 and a one year high of $147.50. The business’s 50-day simple moving average is $122.33 and its 200 day simple moving average is $122.04.

Zimmer Biomet (NYSE:ZBHGet Free Report) last announced its earnings results on Thursday, May 2nd. The medical equipment provider reported $1.94 EPS for the quarter, beating the consensus estimate of $1.87 by $0.07. Zimmer Biomet had a return on equity of 12.70% and a net margin of 12.93%. The business had revenue of $1.89 billion for the quarter, compared to the consensus estimate of $1.87 billion. During the same period last year, the business posted $1.89 EPS. The company’s revenue was up 3.2% on a year-over-year basis. On average, sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.1 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 31st. Shareholders of record on Wednesday, June 26th will be paid a dividend of $0.24 per share. The ex-dividend date of this dividend is Wednesday, June 26th. This represents a $0.96 dividend on an annualized basis and a yield of 0.83%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 20.78%.

Analyst Upgrades and Downgrades

ZBH has been the topic of a number of analyst reports. Citigroup increased their price objective on Zimmer Biomet from $134.00 to $140.00 and gave the company a “neutral” rating in a research note on Wednesday, April 3rd. Barclays decreased their price objective on Zimmer Biomet from $130.00 to $125.00 and set an “underweight” rating on the stock in a research note on Friday. Evercore ISI increased their price objective on Zimmer Biomet from $125.00 to $130.00 and gave the company an “in-line” rating in a research note on Thursday, April 4th. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a research note on Thursday. Finally, Truist Financial cut their price objective on Zimmer Biomet from $137.00 to $130.00 and set a “hold” rating on the stock in a report on Friday, May 3rd. One analyst has rated the stock with a sell rating, nine have issued a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $133.75.

View Our Latest Stock Analysis on ZBH

Zimmer Biomet Company Profile

(Free Report)

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

Recommended Stories

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBHFree Report).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.